Biogen shares climb 6.2% after successful Phase 2 trial for optic neuritis drug

NEW YORK (MarketWatch) — Biogen Idec’s BIIB, +5.56% stock was up 6.2% after the company reported Thursday that a treatment for acute optic neuritis it has developed proved to be effective in the second phase of a research study. Optic neuritis causes the myelin sheath surrounding the eye’s optic nerve to decay, often leading to significant loss of visual function or blindness. The treatment works by repairing the sheath around the nerve. The company called the results for the treatment, known as anti-LINGO-1, “encouraging.”


MarketWatch.com – MarketWatch Breaking News Bulletins

Pin It

Comments are closed.